Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28:151–166.PubMedCrossRef 7. Hazan RB, Qiao R, Keren
R, Badano I, Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci 2004, 1014:155–163.PubMedCrossRef 8. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD: EMT tumorigenesis in the mouse mammary gland. Lab Invest Momelotinib 2007, 87:1218–1226.PubMedCrossRef 9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.PubMedCrossRef 10. Zeisberg M, Neilson EG: Biomarkers for epithelial-Fedratinib concentration mesenchymal transitions. J Clin Invest 2009, 119:1429–1437.PubMedCrossRef 11. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577–584.PubMedCrossRef 12. Barberà MJ, Puig I, Domínguez D, Julien-Grille S, Guaita-Esteruelas S, Peiró S, Baulida J, Francí C, Dedhar S, Larue L, García de Herreros A: Regulation of selleck chemical Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 2004, 23:7345–7354.PubMedCrossRef 13. Kim MR, Choi HK,
Cho KB, Kim HS, Kang KW: Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 2009, 100:1834–1841.PubMedCrossRef 14. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12:247–256. 15. Mu Y, Gudey SK, Landström M: Non-Smad signaling pathways. Cell Tissue Res 2012, 347:11–20.PubMedCrossRef 16. Tan W, Zhang
W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M: Tumour-infiltrating regulatory T cells stimulate mammary cancer ZD1839 in vivo metastasis through RANKL-RANK signalling. Nature 2011, 470:548–553.PubMedCrossRef 17. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G: Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2011, 226:780–784.PubMedCrossRef 18. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692–696.PubMedCrossRef 19.